Aarti Drugs Share Price

Aarti Drugs Limited (ADL), incorporated in September, 1984 is a prominent manufacturer of APIs, Pharma Intermediates, and Specialty Chemicals. The Company operates as part of the Aarti Group, a conglomerate with a net worth of USD 900 million. With over 50 compounds for Antibiotics, Anti Protozoal, AntiInflammatory, Antidiabetic, Anti Fungal and Cardioprotectant therapeutic segments, the Company has emerged as market leader in APIs. Company also operates Pinnacle Life Science Private Limited, its wholly owned subsidiary focused on formulation development.The Company has two RD divisions, one in Tarapur and the other in Turbhe, Maharashtra. It has 3 subsidiaries, namely, Pinnacle Life Science Private Limited, Aarti Speciality Chemicals Limited and Pinnacle Chile SpA (foreign subsidiary). Of the above subsidiaries, Pinnacle Life Science Private Limited and Aarti Speciality Chemicals Limited are wholly owned subsidiaries.The manufacturing units of the Company are GMP certified. Their products include Active Pharmaceutical Ingredients (APIs), Steroids, Pharmaceutical Intermediates, and Specialty Chemicals, such as Benzene Sulphonyl Chloride, Benzene Sulphonic Acid/ Ammonium/ Sodium Salt and Benzene Sulphonamide. In 1993, the company implemented the second phase of their backward integration project and set up facilities for glyoxal (the main raw material for imidazoles). During the year 199495, the company commissioned a plant to recover and market ammonium sulphate derived from plant effluents. Also, Rupal Chemical Industries, a group company, was amalgamated with the company.During the year 199697, the company started their production of secnidazole and dichlofenac sodium. During the year 200001, they started the commercial production of Pharmaceutical Ingredients. During the year 200203, the company expanded the production capacity of bulk drugs by 598,000 kg to 17,430,000 kg. During the year 200304, the company further expanded the production capacity of bulk drugs by 588,000 kg to 18,018,000 kg. During the year 200405, the company started commercial production at their newly setup intermediate plant at Tarapur. During the year 200506, the company increased the production capacity of Pharmaceutical by 2,325,000 kg to 24,020,000 kg. They entered into joint venture with Chinese company engaged in Active Pharmaceutical Ingredients (APIs) manufacturing and formed Huanggang Yinhe Aarti Pharmaceutical Company Ltd for manufacturing and selling of APIs in China. Also, they acquired controlling stake in Suyash Laboratories Ltd so as to make the said company a subsidiary of the company.During the year 200607, the company increased the production capacity by 570,000 kg to 24,590,000 kg. During the next year, they increased the production capacity by 399,000 kg to 24,989,000 kg. During the year 200809, they further increased the production capacity of Pharmaceutical by 50,000 kg to 25,000,000 kg.During the year 200910, the company carried out process improvement work in bulk drugs, such as antihistaminic/antiallergic, antiinflammatory and antidiabetic. ADL expanded the production capacity from 25,000,000 kg to 25,716,000 kg. A Scheme of Amalgamation of Suyash Laboratories Ltd., wholly owned subsidiary of the Company, with the Company became operative w.e.f. from 6th July, 2012.During year 2015, Company acquired 100% equity shares in Pinnacle Life Science Pvt. Ltd., situated at Baddi, Himachal Pradesh. During year 2020, Company incorporated 2 overseas Subsidiaries and 1 Domestic subsidiary Company. Pinnacle Chile SpA, incorporated in Santiago, Chile, was established for marketing the formulation of drugs and participating in the tender and private market in Chile. Aarti Speciality Chemicals Limited (Wholly Owned Subsidiary), in Mumbai, was carrying on business of manufacturers, producers, processors, buyers, sellers, importers, exporters or otherwise dealers in Speciality and other chemicals, pharmaceutical and drugs. Company commissioned brownfield expansion of Speciality Chemical Plant at Tarapur, which turned operational effective from May, 2022. The first project, located at the Tarapur Facility, for dermatology products has commenced operation in FY 202425.

Aarti Drugs reported a Q1FY26 revenue of ₹590.51 crore, down -5.1% YoY, with net profit decreased -2.0% to ₹53.97 crore. For the full year FY2025–2026, revenue reached ₹2403.39 crore and profit touched at ₹168.1 crore. As of Sep '25, Aarti Drugs’s market capitalisation stood at ₹4,515.85 crores. Shareholding as of Sep '25 shows promoters holding 54.7%, with FIIs at 2.7%, DIIs at 9.9%, and public at 32.7%.

As of 28 Oct 2025, Aarti Drugs share price is ₹483.6. The stock opened at ₹491.2 and had closed at ₹491.2 the previous day. During today’s trading session, Aarti Drugs share price moved between ₹479.90 and ₹493.10, with an average price for the day of ₹486.50. Over the last 52 weeks, the stock has recorded a low of ₹312.00 and a high of ₹564.05. In terms of performance, Aarti Drugs share price has increased by 37.8% over the past six months and has declined by 19.57% over the last year.